1. Home
  2. CR vs RDY Comparison

CR vs RDY Comparison

Compare CR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crane Company

CR

Crane Company

BUY

Current Price

$180.31

Market Cap

10.7B

Sector

Industrials

ML Signal

BUY

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$13.24

Market Cap

11.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CR
RDY
Founded
1855
1984
Country
United States
India
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
11.6B
IPO Year
2022
2001

Fundamental Metrics

Financial Performance
Metric
CR
RDY
Price
$180.31
$13.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$226.20
$16.90
AVG Volume (30 Days)
496.9K
2.5M
Earning Date
04-27-2026
05-12-2026
Dividend Yield
0.58%
0.52%
EPS Growth
23.96
N/A
EPS
1.14
N/A
Revenue
$2,305,000,000.00
N/A
Revenue This Year
$27.98
$7.72
Revenue Next Year
$5.76
$3.50
P/E Ratio
$158.75
$18.67
Revenue Growth
8.16
N/A
52 Week Low
$159.58
$12.77
52 Week High
$214.31
$16.17

Technical Indicators

Market Signals
Indicator
CR
RDY
Relative Strength Index (RSI) 49.78 44.81
Support Level $177.86 $12.90
Resistance Level $185.01 $14.21
Average True Range (ATR) 6.91 0.26
MACD -0.02 0.00
Stochastic Oscillator 41.04 31.82

Price Performance

Historical Comparison
CR
RDY

About CR Crane Company

Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: